Computational drug discovery

Weill Cornell models which protein degraders will work before the chemistry starts

A Nature Communications model from Weill Cornell argues that a target protein's turnover rate can matter as much as how tightly a degrader binds it, which would reorder where degrader programs spend their optimisation money.